Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Table 4 Studies describing in-hospital mortality in patients with resistant and multidrug-resistant Pseudomonas aeruginosa infections – cause of death identified specifically as Pseudomonas aeruginosa infection

Setting	Author	Study groups (n)	Infection-related In-Hospital Mortality	P-value	Ref
Tertiary Care Center	Cao et al	MDR P. aeruginosa^a (44)	45.5%	<0.05	[57]
	Cao et al	Susceptible P. aeruginosa (68)	7.4%	<0.05	[57]
	Hirakata et al	bla_IMP-positive P. aeruginosa (69)	5.8%	0.02	[69]
	Hirakata et al	bla_IMP-negative P. aeruginosa (247)	1.2%	0.02	[69]
	Tam et al	MDR P. aeruginosa^b (25)	52%	<0.001	[13]
	Tam et al	Susceptible P. aeruginosa (84)	9.5%	<0.001	[13]

^aAbsence of susceptibility to three or more antibiotics: ceftazidime, cefepime, piperacillin, ciprofloxacin, gentamicin, and imipenem or meropenem; ^bAbsence of susceptibility to three or more of the following four classes of agents: antipseudomonal carbapenems, antipseudomonal β-lactams (penicillins and cephalosporins), aminoglycosides, and fluoroquinolones.

ISSN: 2047-2994